Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Marine cyanobacteria are an ancient group of organisms and prolific producers of bioactive secondary metabolites. These compounds are presumably optimized by evolution over billions of years to exert high affinity for their intended biological target in the ecologically relevant organism but likely also possess activity in different biological contexts such as human cells. Screening of marine cyanobacterial extracts for bioactive natural products has largely focused on cancer cell viability; however, diversification of the screening platform led to the characterization of many new bioactive compounds. Targets of compounds have oftentimes been elusive if the compounds were discovered through phenotypic assays. Over the past few years, technology has advanced to determine mechanism of action (MOA) and targets through reverse chemical genetic and proteomic approaches, which has been applied to certain cyanobacterial compounds and will be discussed in this review. Some cyanobacterial molecules are the most-potent-in-class inhibitors and therefore may become valuable tools for chemical biology to probe protein function but also be templates for novel drugs, assuming in vitro potency translates into cellular and in vivo activity. Our review will focus on compounds for which the direct targets have been deciphered or which were found to target a novel pathway, and link them to disease states where target modulation may be beneficial.

[1]  Jiyong Hong,et al.  Largazole: from discovery to broad-spectrum therapy. , 2012, Natural product reports.

[2]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[3]  Qi-Yin Chen,et al.  Improved Total Synthesis and Biological Evaluation of Potent Apratoxin S4 Based Anticancer Agents with Differential Stability and Further Enhanced Activity , 2014, Journal of medicinal chemistry.

[4]  Roberto Dominguez,et al.  Actin structure and function. , 2011, Annual review of biophysics.

[5]  S. Matthew,et al.  Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii. , 2008, Journal of natural products.

[6]  Roger G. Linington,et al.  Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A. , 2009, Journal of natural products.

[7]  P. Scheuer,et al.  Kulokekahilide-1, a cytotoxic depsipeptide from the cephalaspidean mollusk Philinopsis speciosa. , 2002, The Journal of organic chemistry.

[8]  Marcy J. Balunas,et al.  Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. , 2013, Journal of natural products.

[9]  V. Paul,et al.  Combinatorial Strategies by Marine Cyanobacteria: Symplostatin 4, an Antimitotic Natural Dolastatin 10/15 Hybrid that Synergizes with the Coproduced HDAC Inhibitor Largazole , 2009, Chembiochem : a European journal of chemical biology.

[10]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[11]  Phillip Crews,et al.  Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. , 2003, The Journal of organic chemistry.

[12]  Wei Zhang,et al.  Total synthesis of grassystatin A, a probe for cathepsin E function. , 2012, Bioorganic & medicinal chemistry.

[13]  Youichi Fujii,et al.  Isolation of dolastatins 10–15 from the marine mollusc dolabella auricularia☆☆☆ , 1993 .

[14]  K. Abboud,et al.  Total structure determination of grassypeptolide, a new marine cyanobacterial cytotoxin. , 2008, Organic letters.

[15]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[16]  W. Gerwick,et al.  Biosynthesis of radiolabeled curacin A and its rapid and apparently irreversible binding to the colchicine site of tubulin. , 1999, Archives of biochemistry and biophysics.

[17]  J. Pelletier,et al.  Target identification using drug affinity responsive target stability (DARTS). , 2009, Proceedings of the National Academy of Sciences of the United States of America.

[18]  O. Hurko Target-based drug discovery, genetic diseases, and biologics , 2012, Neurochemistry International.

[19]  L. Ekonomou,et al.  Is copper chelation an effective anti-angiogenic strategy for cancer treatment? , 2013, Medical hypotheses.

[20]  A. Ganesan,et al.  Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. , 2009, Current cancer drug targets.

[21]  V. Paul,et al.  Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. , 2008, Journal of the American Chemical Society.

[22]  Jonathan Puddick,et al.  Lagunamides A and B: cytotoxic and antimalarial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula. , 2010, Journal of natural products.

[23]  Andrew T. Fenley,et al.  The Carmaphycins: New Proteasome Inhibitors Exhibiting an α,β‐Epoxyketone Warhead from a Marine Cyanobacterium , 2012, ChemBioChem.

[24]  Richard E. Moore,et al.  Isolation and structure determination of lyngbyastatin 3, a lyngbyastatin 1 homologue from the marine cyanobacterium Lyngbya majuscula. Determination of the configuration of the 4-amino-2,2-dimethyl-3-oxopentanoic acid unit in majusculamide C, dolastatin 12, lyngbyastatin 1, and lyngbyastatin 3 from , 2003, Journal of natural products.

[25]  R. De Francesco,et al.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Gerwick,et al.  Natural products chemistry and taxonomy of the marine cyanobacterium Blennothrix cantharidosmum. , 2008, Journal of natural products.

[27]  Yechun Xu,et al.  Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases. , 2012, Journal of medicinal chemistry.

[28]  W. Gerwick,et al.  Structure, Synthesis, and Biological Properties of Kalkitoxin, a Novel Neurotoxin from the Marine Cyanobacterium Lyngbya majuscula , 2000 .

[29]  W. Gerwick,et al.  Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium , 2006 .

[30]  S. Matthew,et al.  Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp. , 2007, Journal of natural products.

[31]  Herbert Waldmann,et al.  Target identification for small bioactive molecules: finding the needle in the haystack. , 2013, Angewandte Chemie.

[32]  S. Merajver,et al.  Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  W. Gerwick,et al.  Antillatoxin is a sodium channel activator that displays unique efficacy in heterologously expressed rNav1.2, rNav1.4 and rNav1.5 alpha subunits , 2010, BMC Neuroscience.

[34]  Roger G. Linington,et al.  Total synthesis, stereochemical assignment, and antimalarial activity of gallinamide A. , 2011, Chemistry.

[35]  R. Bates,et al.  Dolastatin 11 connects two long-pitch strands in F-actin to stabilize microfilaments. , 2003, Journal of molecular biology.

[36]  Xuedong Liu,et al.  Largazole and Its Derivatives Selectively Inhibit Ubiquitin Activating Enzyme (E1) , 2012, PloS one.

[37]  W. Gerwick,et al.  The hoiamides, structurally intriguing neurotoxic lipopeptides from Papua New Guinea marine cyanobacteria. , 2010, Journal of natural products.

[38]  B. Law,et al.  Anticolon Cancer Activity of Largazole, a Marine-Derived Tunable Histone Deacetylase Inhibitor , 2010, Journal of Pharmacology and Experimental Therapeutics.

[39]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[40]  L. Pirola,et al.  Therapeutic potential of activators and inhibitors of sirtuins , 2010, BioFactors.

[41]  K. Suenaga,et al.  Isolation and stereostructure of aurilide, a novel cyclodepsipeptide from the Japanese sea hare Dolabella auricularia , 1996 .

[42]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[43]  G. Harrigan,et al.  The cyanobacterial origin of potent anticancer agents originally isolated from sea hares. , 2002, Current medicinal chemistry.

[44]  W. Gerwick,et al.  The neurotoxic lipopeptide kalkitoxin interacts with voltage-sensitive sodium channels in cerebellar granule neurons. , 2005, Toxicology letters.

[45]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[46]  Brian C. Smith,et al.  Mechanisms and molecular probes of sirtuins. , 2008, Chemistry & biology.

[47]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[48]  W. Kolch,et al.  The secret life of kinases: functions beyond catalysis , 2011, Cell Communication and Signaling.

[49]  Jiyong Hong,et al.  Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties. , 2014, ACS medicinal chemistry letters.

[50]  D. Sept,et al.  Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin. , 2004, Biochemistry.

[51]  W. Gerwick,et al.  Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. , 2002, Journal of natural products.

[52]  G. Chlipala,et al.  Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discovery. , 2011, Current drug targets.

[53]  S. Carmeli,et al.  Action of tolytoxin on cell morphology, cytoskeletal organization, and actin polymerization. , 1993, Cell motility and the cytoskeleton.

[54]  William H Gerwick,et al.  The Identification and Characterization of the Marine Natural Product Scytonemin as a Novel Antiproliferative Pharmacophore , 2002, Journal of Pharmacology and Experimental Therapeutics.

[55]  Hiroaki Sasaki,et al.  Cell-morphology profiling of a natural product library identifies bisebromoamide and miuraenamide A as actin filament stabilizers. , 2011, ACS chemical biology.

[56]  T. Kouzarides Chromatin Modifications and Their Function , 2007, Cell.

[57]  W. Gerwick,et al.  Structure of Curacin A, a Novel Antimitotic, Antiproliferative and Brine Shrimp Toxic Natural Product from the Marine Cyanobacterium Lyngbya majuscula , 1994 .

[58]  H. Luesch,et al.  The molecular pharmacology of symplostatin 1: A new antimitotic dolastatin 10 analog , 2003, International journal of cancer.

[59]  C. Smith,et al.  Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. , 1994, Cancer research.

[60]  V. Paul,et al.  Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. , 2001, Journal of the American Chemical Society.

[61]  Olivier Elemento,et al.  Using transcriptome sequencing to identify mechanisms of drug action and resistance , 2011, Nature chemical biology.

[62]  L. T. Tan Pharmaceutical agents from filamentous marine cyanobacteria. , 2013, Drug discovery today.

[63]  Yuqing Liu,et al.  Total synthesis and biological evaluation of grassypeptolide A. , 2013, Chemistry.

[64]  M. Bogyo,et al.  The antimalarial natural product symplostatin 4 is a nanomolar inhibitor of the food vacuole falcipains. , 2012, Chemistry & biology.

[65]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[66]  E. Sausville,et al.  Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin. , 2001, Molecular pharmacology.

[67]  B. Law,et al.  Apratoxin A Reversibly Inhibits the Secretory Pathway by Preventing Cotranslational Translocation , 2009, Molecular Pharmacology.

[68]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[69]  V. Paul,et al.  Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. , 2001, Journal of natural products.

[70]  G. Larson,et al.  Interaction of the antitumor compound cryptophycin-52 with tubulin. , 2000, Biochemistry.

[71]  Herbert Waldmann,et al.  From protein domains to drug candidates – natural products as guiding principles in , 2002 .

[72]  H. Kwak,et al.  In Vitro and In Vivo Osteogenic Activity of Largazole. , 2011, ACS medicinal chemistry letters.

[73]  W. Gerwick,et al.  Isolation and structure of five lyngbyabellin derivatives from a Papua New Guinea collection of the marine cyanobacterium Lyngbya majuscula , 2005 .

[74]  H. Overkleeft,et al.  Proteasome inhibitors: an expanding army attacking a unique target. , 2012, Chemistry & biology.

[75]  M. K. Harper,et al.  Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. , 2009, Bioorganic & medicinal chemistry.

[76]  S. Matthew,et al.  Cytotoxic halogenated macrolides and modified peptides from the apratoxin-producing marine cyanobacterium Lyngbya bouillonii from Guam. , 2010, Journal of natural products.

[77]  Lik Tong Tan,et al.  Bioactive natural products from marine cyanobacteria for drug discovery. , 2007, Phytochemistry.

[78]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.

[79]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[80]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[81]  W. Gerwick,et al.  Antillatoxin, a Novel Lipopeptide, Enhances Neurite Outgrowth in Immature Cerebrocortical Neurons through Activation of Voltage-Gated Sodium Channels , 2010, Journal of Pharmacology and Experimental Therapeutics.

[82]  W. Gerwick,et al.  Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the marine cyanobacteria Lyngbya majuscula and Lyngbya sordida. , 2008, Journal of natural products.

[83]  R. Payne,et al.  Total synthesis and antimalarial activity of symplostatin 4. , 2010, Organic letters.

[84]  G. Schulz,et al.  Binding structure of elastase inhibitor scyptolin A. , 2003, Chemistry & biology.

[85]  L. T. Tan Filamentous tropical marine cyanobacteria: a rich source of natural products for anticancer drug discovery , 2010, Journal of Applied Phycology.

[86]  M. Bagherzadeh,et al.  Density functional theory studies of oxygen and carbonate binding to a dicopper patellamide complex. , 2008, Journal of inorganic biochemistry.

[87]  B. Bassler,et al.  Quorum sensing in bacteria. , 2001, Annual review of microbiology.

[88]  L. Dai,et al.  Total synthesis and stereochemical revision of lagunamide A. , 2012, Chemical communications.

[89]  Richard E. Moore,et al.  Structurally diverse new alkaloids from Palauan collections of the apratoxin-producing marine cyanobacterium Lyngbya sp. ☆ , 2002 .

[90]  Makoto Muroi,et al.  Target identification of small molecules based on chemical biology approaches. , 2013, Molecular bioSystems.

[91]  W. Gerwick,et al.  Antillatoxin and kalkitoxin, ichthyotoxins from the tropical cyanobacterium Lyngbya majuscula, induce distinct temporal patterns of NMDA receptor-mediated neurotoxicity. , 1999, Toxicon : official journal of the International Society on Toxinology.

[92]  V. Paul,et al.  Malyngolide from the cyanobacterium Lyngbya majuscula interferes with quorum sensing circuitry. , 2010, Environmental microbiology reports.

[93]  K. Suenaga,et al.  Aurilide, a cytotoxic depsipeptide from the sea hare Dolabella auricularia: isolation, structure determination, synthesis, and biological activity , 2004 .

[94]  Vipin Chandra Kalia,et al.  Quorum sensing inhibitors: an overview. , 2013, Biotechnology advances.

[95]  W. Gerwick,et al.  Honaucins A-C, potent inhibitors of inflammation and bacterial quorum sensing: synthetic derivatives and structure-activity relationships. , 2012, Chemistry & biology.

[96]  D. Hughes Microbial genetics: Exploiting genomics, genetics and chemistry to combat antibiotic resistance , 2003, Nature Reviews Genetics.

[97]  Richard E. Moore,et al.  New apratoxins of marine cyanobacterial origin from Guam and Palau. , 2002, Bioorganic & medicinal chemistry.

[98]  F. Koehn Natural Products and Cancer Drug Discovery , 2013 .

[99]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[100]  J. Mccammon,et al.  The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L. , 2014, Journal of natural products.

[101]  Shin-ichi Sato,et al.  Biochemical target isolation for novices: affinity-based strategies. , 2010, Chemistry & biology.

[102]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[103]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[104]  P. Scheuer,et al.  Kulokekahilide-2, a cytotoxic depsipeptide from a cephalaspidean mollusk Philinopsis speciosa. , 2004, Journal of natural products.

[105]  M. Uesugi,et al.  Marine natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin. , 2011, Chemistry & biology.

[106]  B. Mellado,et al.  A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer , 2004, International Journal of Gynecologic Cancer.

[107]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[108]  L. Morris,et al.  Conformational change in the thiazole and oxazoline containing cyclic octapeptides, the patellamides. Part 1. Cu2+ and Zn2+ induced conformational change , 2002 .

[109]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[110]  W. Gerwick,et al.  Evolved Diversification of a Modular Natural Product Pathway: Apratoxins F and G, Two Cytotoxic Cyclic Depsipeptides from a Palmyra Collection of Lyngbya bouillonii , 2010, Chembiochem : a European journal of chemical biology.

[111]  Brian C. Smith,et al.  Chemical mechanisms of histone lysine and arginine modifications. , 2009, Biochimica et biophysica acta.

[112]  P. Scheuer,et al.  Malevamide D: isolation and structure determination of an isodolastatin H analogue from the marine cyanobacterium Symploca hydnoides. , 2002, Journal of natural products.

[113]  Hendrik Luesch,et al.  Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. , 2009, Journal of medicinal chemistry.

[114]  Roger G Linington,et al.  Almiramides A-C: discovery and development of a new class of leishmaniasis lead compounds. , 2010, Journal of medicinal chemistry.

[115]  Jacques Ravel,et al.  Natural combinatorial peptide libraries in cyanobacterial symbionts of marine ascidians , 2006, Nature chemical biology.

[116]  J. Clardy,et al.  Atomic structure of the trypsin-A90720A complex: a unified approach to structure and function. , 1994, Chemistry & biology.

[117]  Bradley S Moore,et al.  Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. , 2012, Chemistry & biology.

[118]  Hendrik Luesch,et al.  Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity , 2011, ACS medicinal chemistry letters.

[119]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[120]  Peter G Schultz,et al.  A functional genomics approach to the mode of action of apratoxin A , 2006, Nature chemical biology.

[121]  Y. Li,et al.  Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy , 2009, The Journal of cell biology.

[122]  Lilibeth A. Salvador,et al.  Discovery and mechanism of natural products as modulators of histone acetylation. , 2012, Current drug targets.

[123]  A. Kraft,et al.  Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[124]  M. Yoshida,et al.  FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. , 1998, Experimental cell research.

[125]  V. Paul,et al.  Isolation, structure determination, and biological activity of Lyngbyabellin A from the marine cyanobacterium lyngbya majuscula. , 2000, Journal of natural products.

[126]  H. Simon,et al.  Cathepsins and their involvement in immune responses. , 2010, Swiss medical weekly.

[127]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[128]  K D Paull,et al.  Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. , 1991, The Journal of biological chemistry.

[129]  C. Crews,et al.  From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. , 2013, Natural product reports.

[130]  G. Harrigan,et al.  Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. , 1998, Journal of natural products.

[131]  R. Cerny,et al.  Isolation and structure of the cytostatic depsipeptide dolastatin 13 from the sea hare Dolabella auricularia , 1989 .

[132]  S. Saito Toxins affecting actin filaments and microtubules. , 2009, Progress in molecular and subcellular biology.

[133]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[134]  Sixue Chen,et al.  Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms , 2013, Oncogene.

[135]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[136]  V. Paul,et al.  Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells. , 2013, Journal of medicinal chemistry.

[137]  V. Paul,et al.  Lyngbyoic acid, a "tagged" fatty acid from a marine cyanobacterium, disrupts quorum sensing in Pseudomonas aeruginosa. , 2011, Molecular bioSystems.

[138]  Feng Cong,et al.  Chemical genetics-based target identification in drug discovery. , 2012, Annual review of pharmacology and toxicology.

[139]  P. Jensen,et al.  Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A , 2007 .

[140]  V. Israel,et al.  Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. , 2003, Lung cancer.

[141]  Richard E. Moore,et al.  Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV 224 , 1994 .

[142]  V. Paul,et al.  Grassypeptolides as Natural Inhibitors of Dipeptidyl Peptidase 8 and T‐Cell Activation , 2014, Chembiochem : a European journal of chemical biology.

[143]  J. Cooper,et al.  Effects of cytochalasin and phalloidin on actin , 1987, The Journal of cell biology.

[144]  Erin E. Carlson,et al.  Natural products as chemical probes. , 2010, ACS chemical biology.

[145]  S. Schreiber,et al.  Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. , 2008, Journal of the American Chemical Society.

[146]  Richard E. Moore,et al.  Structure determination, conformational analysis, chemical stability studies, and antitumor evaluation of the cryptophycins. Isolation of 18 new analogs from Nostoc sp. strain GSV 224 , 1995 .

[147]  M. Muda,et al.  Model organisms and target discovery. , 2004, Drug discovery today. Technologies.

[148]  Jonathan Puddick,et al.  Lagunamide C, a cytotoxic cyclodepsipeptide from the marine cyanobacterium Lyngbya majuscula. , 2011, Phytochemistry.

[149]  S. Schreiber,et al.  Synthesis of Natural and Modified Trapoxins, Useful Reagents for Exploring Histone Deacetylase Function , 1996 .

[150]  W. Gerwick,et al.  Antillatoxin is a marine cyanobacterial toxin that potently activates voltage-gated sodium channels , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[151]  Hendrik Luesch,et al.  Towards high-throughput characterization of small molecule mechanisms of action. , 2006, Molecular bioSystems.

[152]  V. Paul,et al.  Modular strategies for structure and function employed by marine cyanobacteria: characterization and synthesis of pitinoic acids. , 2013, Organic letters.

[153]  W. Gerwick,et al.  Hoiamide a, a sodium channel activator of unusual architecture from a consortium of two papua new Guinea cyanobacteria. , 2009, Chemistry & biology.

[154]  T. Robak,et al.  Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity. , 2007, Mini reviews in medicinal chemistry.

[155]  W. Gerwick,et al.  Aurilides B and C, cancer cell toxins from a Papua New Guinea collection of the marine cyanobacterium Lyngbya majuscula. , 2006, Journal of natural products.

[156]  Wei Zhang,et al.  Total synthesis and stereochemical reassignment of tasiamide , 2008, Journal of peptide science : an official publication of the European Peptide Society.

[157]  G. Harrigan,et al.  Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages. , 1998, Journal of natural products.

[158]  D. Christianson,et al.  Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. , 2011, Journal of the American Chemical Society.

[159]  Joachim Müller,et al.  New approaches for the identification of drug targets in protozoan parasites. , 2013, International review of cell and molecular biology.

[160]  S. Aoki,et al.  ARENASTATIN A, A POTENT CYTOTOXIC DEPSIPEPTIDE FROM THE OKINAWAN MARINE SPONGE DYSIDEA ARENARIA , 1994 .

[161]  K. Shin‐ya,et al.  Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. , 2001 .

[162]  W. Gerwick,et al.  Antillatoxin B, a neurotoxic lipopeptide from the marine cyanobacterium Lyngbya majuscula. , 2001, Journal of natural products.

[163]  T. Molinski,et al.  Symplocin A, a linear peptide from the Bahamian cyanobacterium Symploca sp. Configurational analysis of N,N-dimethylamino acids by chiral-phase HPLC of naphthacyl esters. , 2012, Journal of natural products.

[164]  William H Gerwick,et al.  Structure and biosynthesis of the jamaicamides, new mixed polyketide-peptide neurotoxins from the marine cyanobacterium Lyngbya majuscula. , 2004, Chemistry & biology.

[165]  J. Kwan,et al.  Evaluation of class I HDAC isoform selectivity of largazole analogues. , 2014, Bioorganic & medicinal chemistry letters.

[166]  S. Wilkinson,et al.  Trypanocidal drugs: mechanisms, resistance and new targets , 2009, Expert Reviews in Molecular Medicine.

[167]  Roger G. Linington,et al.  Examination of the mode of action of the almiramide family of natural products against the kinetoplastid parasite Trypanosoma brucei. , 2013, Journal of natural products.

[168]  N. Schork,et al.  Kinase mutations in human disease: interpreting genotype–phenotype relationships , 2010, Nature Reviews Genetics.

[169]  Richard E. Moore,et al.  Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452. , 2002, Journal of natural products.

[170]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[171]  W. Gerwick,et al.  Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction. , 2012, Bioorganic & medicinal chemistry letters.

[172]  Hendrik Luesch,et al.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. , 2008, Journal of the American Chemical Society.

[173]  H. Osada,et al.  Morphobase, an encyclopedic cell morphology database, and its use for drug target identification. , 2012, Chemistry & biology.

[174]  W. Gerwick,et al.  Antillatoxin: An Exceptionally Ichthyotoxic Cyclic Lipopeptide from the Tropical Cyanobacterium Lyngbya majuscula , 1995 .

[175]  S. Friedman,et al.  A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor‐β and vascular endothelial growth factor signalling , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[176]  E. Hamel,et al.  Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. , 1990, Biochemical pharmacology.

[177]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[178]  W. Gerwick,et al.  Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. , 2009, Journal of Organic Chemistry.

[179]  Richard E. Moore,et al.  The isolation and structure elucidation of Tasiamide B, a 4-amino-3-hydroxy-5-phenylpentanoic acid containing peptide from the marine Cyanobacterium Symploca sp. , 2003, Journal of natural products.

[180]  K. Janda,et al.  Total synthesis of the depsipeptide FR-901375. , 2003, The Journal of organic chemistry.

[181]  G. Superti-Furga,et al.  Target profiling of small molecules by chemical proteomics. , 2009, Nature chemical biology.

[182]  Christian P. Ridley,et al.  Speciation and biosynthetic variation in four dictyoceratid sponges and their cyanobacterial symbiont, Oscillatoria spongeliae. , 2005, Chemistry & biology.